  The existing adaptive basal-bolus advisor (ABBA) was further developed to
benefit patients under insulin therapy with multiple daily injections (MDI).
Three different in silico experiments were conducted with the DMMS.R simulator
to validate the approach of combined use of self-monitoring of blood glucose
(SMBG) and insulin injection devices, e.g. insulin pen, as are used by the
majority of type 1 diabetes patients under insulin therapy. The proposed
approach outperforms the conventional method, as it increases the time spent
within the target range and simultaneously reduces the risks of hyperglycaemic
and hypoglycaemic events.
